Fate Therapeutics Inc (FATE) — 8-K Filings

8-K Filings (13)

• Fate Therapeutics Files 8-K Report — Oct 27, 2025 Risk: low
  On October 26, 2025, Fate Therapeutics, Inc. filed an 8-K report. The filing primarily concerns other events and includes financial statements and exhibits. No
• Fate Therapeutics Announces CMO Departure and Interim Appointment — Oct 14, 2025 Risk: medium
  On October 10, 2025, Fate Therapeutics, Inc. filed an 8-K report detailing the departure of Dr. Wayne Johnson as Chief Medical Officer. The company also announc
• Fate Therapeutics Files 8-K on Financials and Operations — Aug 12, 2025 Risk: medium
  On August 7, 2025, Fate Therapeutics, Inc. filed an 8-K report detailing results of operations and financial condition. The filing also covers costs associated
• Fate Therapeutics Files 8-K: Director Changes & Bylaw Amendments — May 30, 2025 Risk: medium
  On May 29, 2025, Fate Therapeutics, Inc. filed an 8-K report detailing several key events. These include the departure of directors, the election of new directo
• Fate Therapeutics Files 8-K: Board & Compensation Updates — Jan 6, 2025 Risk: low
  On December 31, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filin
• Fate Therapeutics Announces Executive Changes and Board Election — Nov 29, 2024 Risk: medium
  On November 27, 2024, Fate Therapeutics, Inc. announced the departure of Dr. Wayne V. Saville from his role as Chief Medical Officer. The company also reported
• Fate Therapeutics Director Departs; Filings Detail Compensation — Aug 30, 2024 Risk: medium
  On August 26, 2024, Fate Therapeutics, Inc. announced the departure of Dr. Wayne V. Saville from its Board of Directors. The company also reported on compensato
• Fate Therapeutics Appoints New CMO and CSO — Jul 31, 2024 Risk: medium
  On July 29, 2024, Fate Therapeutics, Inc. announced the appointment of Dr. Nicole A. Shuman as Chief Medical Officer and Dr. Jeffrey S. W. Smith as Chief Scient
• Fate Therapeutics Files 8-K for Charter Amendments — Jun 10, 2024 Risk: low
  On June 7, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation and changes to its fiscal year. The company,
• Fate Therapeutics Files 8-K on Director Changes and Officer Appointments — Jun 7, 2024 Risk: medium
  On June 3, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, the appointment
• Fate Therapeutics Appoints New Directors, One Resigns — May 31, 2024 Risk: medium
  On May 30, 2024, Fate Therapeutics, Inc. announced changes in its board of directors. Dr. Paul R. Hastings and Dr. Jeffrey W. Runge have been appointed to the B
• Fate Therapeutics Adopts New Equity Incentive Plan — May 9, 2024 Risk: low
  On May 9, 2024, Fate Therapeutics, Inc. filed an 8-K report detailing the adoption of a new equity incentive plan, the "2024 Equity Incentive Plan," and the app
• Fate Therapeutics Files 8-K: Material Agreement & Equity Sales — Mar 21, 2024 Risk: medium
  On March 19, 2024, Fate Therapeutics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX